|
| Jubilant Q4 net dips 81%, outlines Rs 250 cr capex |
| Press Trust of India / Mumbai Apr 28, 2009, 15:39 IST |
|
Pharma company Jubilant Organosys today reported a consolidated net profit of Rs 12.37 crore for the fourth quarter ended March 31, 2009, as compared to Rs 63.88 crore in the corresponding quarter a year ago, the company said in a filing to the Bombay Stock Exchange.
The total income rose to Rs 853.94 crore during the March quarter from Rs 696.96 crore in the same period last fiscal.
On FY10 outlook, the company said it expects to report top-line growth of over 15 per cent driven by the pharma and life sciences business (PLSPS). The company has planned a capital expenditure of Rs 250 crore for FY10.
In May 2008, Jubilant acquired Canada-based Draxis Speciality Pharmaceuticals Inc for $253 million and Specialty Molecules for an undisclosed amount. Hence, the previous year's figures are not comparable with that of the present quarters, the company said.
"We are happy to conclude FY 2009 with a record top line growth, which is fuelled by the robust performance of our PLSPS. Despite the global economic slowdown, the company has reported a robust organic growth...," Jubilant Organosys Chairman and Managing Director Shyam S Bhartia said.
On a standalone basis, the company reported a net loss of Rs 15.29 crore in March quarter of FY09. It had a net profit of Rs 82.80 crore in the year-ago period.
|
|
|
|
|
|
|
|
|
|
 Read Business news in |  |
|
|
|
|
|
|
Advertisements |
|
|
|
|
|
|
|
|
|
|
Content Guide
